|Mr. Andrew R. Robbins M.B.A.||Pres, CEO & Director||N/A||N/A||1976|
|Mr. John L. Green C.A., CPA||CFO & Principal Accounting Officer||N/A||N/A||1980|
|Mr. Brad Barnett||Chief Technology Officer||N/A||N/A||N/A|
|Dr. John Robinson Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Erin Schellhammer||Chief People Officer||N/A||N/A||N/A|
|Dr. Jessica Sachs M.D.||Chief Medical Officer||N/A||N/A||1975|
|Ms. Sara Saltzman||Sr. VP of Regulatory Affairs||N/A||N/A||N/A|
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Cogent Biosciences, Inc. has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of CGT9486 and CGT0206 inhibitors. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Cogent Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.